TRex Bio, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on discovering and developing precision therapeutics to treat moderate-to-severe immune-mediated diseases by targeting regulatory T cells.
Subscribe to see TRex Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
TRex Bio is a biotech company headquartered in South San Francisco, United States. It is publicly listed (TRXB) with a market capitalisation of $387M. Xcout tracks 29 named people at TRex Bio, including Marion Johnston Erwin Jr. (Chairman & CEO).
As of 17 November 2026. Source: Xcout Intel.
23 more named people on record for TRex Bio, with roles, board committees and tenure — see the full roster →
6 corporate events on record, with sources — see the full timeline →
A few of TRex Bio's closest competitors — see the full list of competitors and alternatives →
Sonoma Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, California.
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
Egle Therapeutics SAS is a clinical-stage biotechnology company headquartered in Paris, France, that develops precision medicines designed to modulate regulatory T cells.
Ouro Medicines is a biotechnology company headquartered in South San Francisco, California, developing immune reset therapeutics for chronic immune-mediated diseases.
GentiBio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with an additional office in Seattle, Washington, developing engineered regulatory T cell (Treg) therapies to cure Type 1 diabetes and other autoimmune diseases.
Slate Bio, Inc. is a privately held pre-clinical stage biotechnology company founded in 2020 and headquartered in Charlottesville, Virginia, specializing in T regulatory therapies to address autoimmune diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about TRex Bio? Suggest a correction · Work at TRex Bio? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.